Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

Table 5 Relation between thymus gland pathology of the studied patients and studied scores

		Thymus gland			Test value	P value	Sig.
Total (52 patients)		Normal (31 patients)	Hyperplasia (15 patients)	Thymoma (6 patients)	Test value	P value	Sig.
Initial QMG score	Mean ± SD	25.10 ± 3.48	28.87 ± 2.23	31.50 ± 1.52	15.770^a	0.001	HS
Initial QMG score	Range	19-31	24-32	30-34	15.770^a	0.001	HS
QMG score after 1 month	Mean ± SD	16.32 ± 3.50	19.40 ± 3.50	25.67 ± 5.47	16.565^a	0.001	HS
QMG score after 1 month	Range	11-23	11-24	15-30	16.565^a	0.001	HS
QMG change	Median (IQR)	−34.62 (−43.48-−23.81)	−31.25 (−35.71-−25)	−15.08 (−19.35-−6.67)	6.488	0.039	S
QMG change	Range	−58.06-−13.64	−58.06-−8.33	−53.13-0	6.488	0.039	S
Test value		9.011	3.528	2.403
P value		0.001	0.002	0.061
Initial QOL score	Mean ± SD	45.71 ± 3.93	49.93 ± 4.22	52.83 ± 2.64	11.676^a	0.001	HS
Initial QOL score	Range	39-54	44-57	49-57	11.676^a	0.001	HS
QOL score after 1 month	Mean ± SD	35.52 ± 6.47	41.33 ± 5.07	48.50 ± 6.83	13.166^a	0.001	HS
QOL score after 1 month	Range	25-49	30-48	36-54	13.166^a	0.001	HS
QOL change	Median (IQR)	−20 (−30.23-−10.64)	−14.58 (−18.87 – −11.11)	−5.52 (−11.54-0)	7.080	0.029	S
QOL change	Range	−50-−4.76	−41.51-−4.44	−33.33-8.16	7.080	0.029	S
Test value		7.360	2.517	1.415
P value		0.001	0.021	0.216

NS non-significant, S significant, HS highly significant, QOL quality of life, QMG quantitative myasthenia gravis, SD standard deviation
^aOne-way ANOVA